ReviewJournal of translational medicine2026

Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.

Vincenzo Quagliariello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.